Skip to main content

Advertisement

SpringerLink
Log in

The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Recent studies have shown that immune-related adverse events (irAEs) caused by immune checkpoint inhibitors (ICIs) were correlated with favorable clinical outcome in patients with melanoma. However, in metastatic renal cell carcinoma (mRCC) patients, there have been few reports about the correlation between irAEs and clinical efficacy of anti-programmed cell death protein-1 (PD-1) therapy.

Methods

We retrospectively investigated 160 mRCC patients who started nivolumab monotherapy between September 2016 and July 2019. IrAEs were defined as patients’ AEs having a potential immunological basis that required close follow-up, or immunosuppressive therapy. We compared the data of patients who received nivolumab into two groups based on the occurrence of irAEs and assessed clinical efficacy in both groups.

Results

Of all mRCC patients, 47 patients (29.4%) developed irAEs. In patients who developed irAEs, the objective response rate and disease control rate were 38.8% and 77.6%, which were significantly higher when compared to that in patients without irAEs (p = 0.012 and p < 0.001, respectively). Furthermore, the incidence of irAEs was significantly associated with an increase in progression-free survival (PFS) [Hazard ratio (HR) = 0.4867; p = 0.0006] and overall survival (OS) (HR = 0.526; p = 0.0252). Importantly, PFS and OS seemed to be similar in patients who discontinued treatment because of irAEs and in those who did not discontinue because of irAEs (p = 0.36 and p = 0.35, respectively).

Conclusion

Development of irAEs strongly correlates with clinical benefit for mRCC patients receiving nivolumab monotherapy in real-world settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

ccRCC:

Clear cell renal carcinoma

CTCAE:

Common Terminology Criteria for Adverse Event

DCR:

Disease control rate

ICI:

Immune checkpoint inhibitor

iRAEs:

Immune-related adverse events

mRCC:

Metastatic renal cell carcinoma

ORR:

Objective response rate

OS:

Overall survival

PD-1:

Programmed death 1

PD-L1:

Programmed death-ligand 1

PFS:

Progression-free survival

RCC:

Renal cell carcinoma

References

  1. Bray FFJ, Soerjomataram I, Siegel RL et al (2020) Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 70:313

    Google Scholar 

  2. Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128

    Article  CAS  Google Scholar 

  3. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454

    Article  CAS  Google Scholar 

  4. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982

    Article  CAS  Google Scholar 

  5. Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813

    Article  CAS  Google Scholar 

  6. Tomita Y, Fukasawa S, Shinohara N et al (2017) Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin Oncol 47:639–646

    Article  Google Scholar 

  7. Verzoni E, Carteni G, Cortesi E et al (2019) Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 7:99

    Article  Google Scholar 

  8. Yip SM, Wells C, Moreira R et al (2018) Checkpoint inhibitors in patients with metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer 124:3677–3683

    Article  CAS  Google Scholar 

  9. Hinata N, Yonese J, Masui S et al (2020) A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data. Int J Clin Oncol. https://doi.org/10.1007/s10147-020-01692-z

    Article  PubMed  PubMed Central  Google Scholar 

  10. Masuda K, Shoji H, Nagashima K et al (2019) Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 19:974

    Article  Google Scholar 

  11. Nakamura Y, Tanaka R, Asami Y et al (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol 44:117–122

    Article  CAS  Google Scholar 

  12. Okada N, Kawazoe H, Takechi K et al (2019) Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study. Clin Ther 41:59–67

    Article  CAS  Google Scholar 

  13. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  Google Scholar 

  14. Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350–1355

    Article  CAS  Google Scholar 

  15. Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168

    Article  CAS  Google Scholar 

  16. Sato K, Akamatsu H, Murakami E et al (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115:71–74

    Article  Google Scholar 

  17. Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886–894

    Article  CAS  Google Scholar 

  18. Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374–378

    Article  Google Scholar 

  19. Schadendorf D, Wolchok JD, Hodi FS et al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807–3814

    Article  CAS  Google Scholar 

  20. Verzoni E, Cartenì G, Cortesi E et al (2019) Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 7:99

    Article  Google Scholar 

  21. Ishihara H, Takagi T, Kondo T et al (2019) Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol 37:355.e321-e329

    Article  Google Scholar 

  22. Kato T, Tomiyama E, Koh Y et al (2020) A potential mechanism of anticancer immune response coincident with immune-related adverse events in patients with renal cell carcinoma. Anticancer Res 40:4875–4883

    Article  CAS  Google Scholar 

  23. Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19:1480–1492

    Article  CAS  Google Scholar 

  24. Pollack MH, Betof A, Dearden H et al (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29:250–255

    Article  CAS  Google Scholar 

  25. Simonaggio A, Michot JM, Voisin AL et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.1022

    Article  PubMed  PubMed Central  Google Scholar 

  26. Weber JS, Hodi FS, Wolchok JD et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785–792

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Taigo Kato, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Ryoichi Imamura, Norio Nonomura & Motohide Uemura

  2. Department of Urological Immuno-Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan

    Taigo Kato & Motohide Uemura

  3. Department of Urology, Osaka International Cancer Institute, Chuo-ku, Osaka, 541-8567, Japan

    Akira Nagahara & Kazuo Nishimura

  4. Department of Urology, Osaka General Medical Center, Sumiyoshi-ku, Osaka, 558-8558, Japan

    Norihiko Kawamura, Seiji Yamaguchi & Tetsuya Takao

  5. Departments of Urology, Osaka Rosai Hospital, Sakai, Osaka, 591-8025, Japan

    Wataru Nakata & Masao Tsujihata

  6. Department of Urology, Osaka Police Hospital, Tenoji-ku, Osaka, 543-0035, Japan

    Tetsuji Soda & Shingo Takada

  7. Department of Urology, National Hospital Organization Osaka National Hospital, Chuo-ku, Osaka, 540-0006, Japan

    Kyosuke Matsuzaki & Kensaku Nishimura

Authors
  1. Taigo Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Nagahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Norihiko Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wataru Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuji Soda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kyosuke Matsuzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Koji Hatano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsunari Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takeshi Ujike
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ryoichi Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kensaku Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shingo Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Masao Tsujihata
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Seiji Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tetsuya Takao
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Kazuo Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Norio Nonomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Motohide Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TK was responsible for the study conception and design, and conducted the study, data collection and analysis, drafting the manuscript. AN, NK, WN, TS, KM, KH, AK, TU, RI, KN, SY, TT, MT, ST, KN, NN, and MU conducted the study, data collection and analysis, drafting the manuscript, and manuscript revision. All authors read and approved the final manuscript for submission.

Corresponding author

Correspondence to Taigo Kato.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 126 kb)

Supplementary file1 (XLXS 15 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kato, T., Nagahara, A., Kawamura, N. et al. The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study. Int J Clin Oncol 26, 954–961 (2021). https://doi.org/10.1007/s10147-021-01872-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-021-01872-5

Keywords

Search

Navigation